St Germain D J CO Inc Lineage Cell Therapeutics, Inc. Transaction History
St Germain D J CO Inc
- $2.22 Billion
- Q2 2025
A detailed history of St Germain D J CO Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, St Germain D J CO Inc holds 2 shares of LCTX stock, worth $2. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2
Previous 2
-0.0%
Holding current value
$2
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
141Shares Held
108MCall Options Held
8KPut Options Held
3K-
Broadwood Capital Inc New York, NY49.6MShares$58 Million1.86% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$11.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$10.4 Million0.0% of portfolio
-
Defender Capital, Llc.6.79MShares$7.94 Million2.42% of portfolio
-
Raffles Associates LP New York, NY5.64MShares$6.6 Million3.45% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $199M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...